United Therapeutics Corporation
- UTHR
- NASDAQ
- Biotechnology
- Pulmonary Hypertension Drugs
- Rare Disease Biotech
$533.12
Today −1.55%Quote Oct 16, 2026, 08:00 PM UTC
+7.21%over the last month
Max drawdown −6.8%From 1-month high −6.7%3 months +0.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$22.87B
Quote Oct 16
Next earnings
Nov 4
Expected, not confirmed
Analyst target
$630.33
+18.2% from here
Floor
$529.87
0.6% below price
Where the price sits
30 analysts
Analyst range, low to high
$368.00$735.00
- Price $533.12
- Resistance $543.06–$548.52
- Consensus $630.33
The price is just above its floor and right under resistance. Analysts' average target sits about 18% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about UTHRPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $783.3M
- Tyvaso$452.6M57.8%
- Remodulin$126.3M16.1%
- Orenitram$125.7M16.0%
- Unituxin$65.2M8.3%
- Product and Service, Other$6.8M0.9%
- Adcirca$6.7M0.9%
Industry
Biotechnology
Employees
1,400